Sobi Grants Portal

Sobi Grants Portal is sponsored by Sobi North America. Considers educational grant requests aligned with current approved products and therapeutic areas, including research grants.

* Investigator sponsored studies * Managed Access Programmes * Clinical studies and data privacy * Anslag till medicinsk forskning Sobi welcomes requests for grants to fund independent medical education and research. These grants are provided to support bona fide, independent medical educational initiatives.

Their primary purpose is to maintain, develop, or increase the knowledge, skills, and/or professional performance of healthcare professionals. Educational grants can include activities for. but are not limited to disease awareness, patient education and medical writing support.

Educational initiatives may be accredited or non-accredited and must be in the field of Sobi's therapeutic areas of interest. Please see below. These grants are provided to advance medical or scientific knowledge.

Sobi welcomes requests for grants to fund independent research, in the field of Sobi's therapeutic areas of interest. Sobi also welcomes applications for Investigator Sponsor Studies. Grant support can only be provided to eligible organizations, not to individual healthcare professionals or for the benefit of an individual person or persons.

Eligible organizations (legal entities) may include, but are not limited to: * Academic medical centers and medical universities * Professional medical associations/societies * Accredited continuing medical education providers #### Considerations and minimum requirements Submission of a grant request does not guarantee approval. All decisions regarding funding are made at the discretion of Sobi.

The requester must be prepared to provide additional documentation and/or written clarifications upon request to enable a complete assessment. If approved, a contract will be required to document appropriately the funding purpose and other compliance requirements.

To be considered, each request must: * Be free from Sobi influence * Be free from promotional biases * Seek to close an identified educational gap * Demonstrate value for patients and/or the healthcare sector in terms of advancing research * Be submitted a minimum of 90 days prior to the start date * Provide expected tangible outcomes * Include relevant supporting documents as listed below #### Supporting Documentation * A signed request letter by authorized individual(s) on organizational letterhead and/or from an institutional email account (excluding services like Hotmail and Gmail), which adequately describes how the requested funding will be used, the details of the proposed activity and the anticipated outcomes * Transparent disclosure of the recipient of the funds, including details of any payments to government officials or healthcare professionals (if applicable) and associated rationale (e.g. service description and number of hours for professional fees) * A detailed budget breakdown allowing Sobi to assess the amount of funding requested (lump sum budgets will be rejected) * Whether the activity would be supported by other funding sources or by Sobi only * For events: as applicable, including but not limited to: agenda, hospitality details, venue, details on use of funding used to cover costs of travel or accommodation for healthcare professionals or government officials, expected number of attendees #### What Does Not Fall Under the Grant Definition * Investigator Sponsor Studies * Patient Organisation (PO) requests ### Areas of interest per Therapeutic Area * Research on disease physiopathology and epidemiology * International registries support **Immune thrombocytopenia (ITP)** * Real-world or health outcomes (e.g. patient reported outcomes) registry research * Preclinical/translational studies exploring avatrombopag's mechanism of action in non-ITP diseases (e.g. AA, CIT, MDS) **Paroxysmal nocturnal Haemoglobinuria (PNH), complement mediated kidney diseases** * Real-world or health outcomes (e.g. patient reporter outcomes) registry research **Diffuse large B-cell lymphoma (DLBCL)** * Real-world or health outcomes (e.g. patient reporter outcomes) registry research * Mechanism of action and antigen expression including preclinical research * Treatment sequencing in DLBCL **Chronic Myelofibrosis or malignant diseases that may be driven by JAK2 or NFkB** * Disease management and treatment landscape * Real-world or health outcomes studies (e.g. patient reporter outcomes) registry research **Chronic myelofibrosis and other inflammatory or malignant diseases that may be driven by JAK2, NFkB (e.g. CMML, VEXAS)** * Real-world or health outcomes (e.g. patient reported outcomes) registry research **Inflammatory disease that may be driven by JAK2, NFkB or CSF1R (e.g. VEXAS)** * Disease management and treatment landscape * Real-world or health outcomes studies (e.g. patient reporter outcomes) registry research **Hyperinflammatory and other conditions that may be driven by excess IFNy** * Real-world or health outcomes (e.g. patient reporter outcomes) registry research * The role of IFNγ in driving disease pathophysiology **Complement mediated kidney diseases (Complement 3 Glomerulonephritis and Immunocomplex Membranoproliferative disease)** * Real-World data generation in patients with Complement 3 Glomerulonephritis and Immunocomplex Membranoproliferative disease (C3G/IC-MPGN) (i.e. registry research) * Improvement of patient care and treatment algorithm for patients with C3G/primary IC-MPGN * Medical Education on unmet needs and diagnosis of C3G/primary IC-MPGN **Severe hypertriglyceridemia / Chylomicronemia syndrome** * Real-world or health outcomes (e.g. patient reported outcomes) registry research * International registries support * Research on chylomicronemia syndrome disease physiopathology and epidemiology * Improvement of patient care and treatment algorithm for patients with chylomicronemia syndrome * Medical education on unmet needs and diagnosis of chylomicronemia syndrome Description of intended use of grant Amount requested from Sobi (include currency) Estimated total amount for the project/activity Estimated time for Start of Grant project/activity (month/year) Estimated time for Completion (End) of Grant project/activity (month/year) List of attachments (Request Letter, Project plan, Budget/cost estimate, CVs, institution by-laws, etc.) Allowed file types: pdf, doc, docx, ppt, pptx, xls, xlsx Allowed types: pdf, doc, docx, ppt, pptx, xls, xlsx.

Previous Sobi Grants received by Applicant (timing, amount and brief description of any Sobi Grants in last 3 years) * Healthcare professionals * Supplier terms & conditions We are a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases.

* Patients as equal contributors * Humanitarian programmes * Trusted education source * Patient Engagement in acquisitions * Continuous and transparent communication * Define and deliver on shared objectives * Informed decision making (IDM) * Patient Engagement and experience data * Innovate disease awareness campaigns * Articles of association Our therapies are concentrated within the areas of Haematology, Immunology and Specialty Care.

* Immune thrombocytopenia (ITP) * Paroxysmal nocturnal haemoglobinuria (PNH) * Diffuse large B-cell lymphoma (DLBCL) * Familial Mediterranean fever (FMF) * Cryopyrin-associated periodic syndromes (CAPS) * Haemophagocytic lymphohistiocytosis (HLH) * Familial Chylomicronemia Syndrome (FCS) * Hereditary Tyrosinaemia Type 1 (HT-1) * Hereditary Transthyretin Amyloidosis (hATTR) * Investigator sponsored studies * Managed Access Programmes * Clinical studies and data privacy * Anslag till medicinsk forskning We contribute to societies by improving access to treatment of rare diseases.

* Sustainability performance * Sustainability governance * Policies and responsibilities * Environmental footprint * Disclosure of Payments to Healthcare * Trade association memberships * Supporting patient organisations Find out more about our business and financial performance. * Historical share price look-up Every day, we work actively to find better ways to understand and meet patient needs.

* Patients as equal contributors * Humanitarian programmes * Trusted education source * Patient Engagement in acquisitions * Continuous and transparent communication * Define and deliver on shared objectives * Informed decision making (IDM) * Patient Engagement and experience data * Innovate disease awareness campaigns * Articles of association * Immune thrombocytopenia (ITP) * Paroxysmal nocturnal haemoglobinuria (PNH) * Diffuse large B-cell lymphoma (DLBCL) * Familial Mediterranean fever (FMF) * Cryopyrin-associated periodic syndromes (CAPS) * Haemophagocytic lymphohistiocytosis (HLH) * Familial Chylomicronemia Syndrome (FCS) * Hereditary Tyrosinaemia Type 1 (HT-1) * Hereditary Transthyretin Amyloidosis (hATTR) * Investigator sponsored studies * Managed Access Programmes * Clinical studies and data privacy * Anslag till medicinsk forskning * Sustainability performance * Sustainability governance * Policies and responsibilities * Environmental footprint * Disclosure of Payments to Healthcare * Trade association memberships * Supporting patient organisations * Historical share price look-up ## Privacy Preference Center ### Manage Consent Preferences * - [x] checkbox label label - [x] checkbox label label - [x] checkbox label label - [x] checkbox label label